(Q33960409)

30 July 2017

1 reference

title

Preventing infectious disease with passive immunization (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

L Zeitlin

1

1 reference

30 July 2017

R A Cone

series ordinal

2

1 reference

30 July 2017

T R Moench

series ordinal

3

1 reference

30 July 2017

K J Whaley

series ordinal

4

1 reference

30 July 2017

publication date

1 May 2000

1 reference

30 July 2017

published in

Microbes and Infection

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

701-708

1 reference

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Passive antibody therapies: progress and continuing challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Further Evidence for Cross-Linking as a Protective Factor in Experimental Cholera: Properties of Antibody Fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Diversity of antibody-mediated immunity at the mucosal barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

The influence of polyvalency on the binding properties of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Antibody affinity—III the role of multivalence

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Selection and evolution of high-affinity human anti-viral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

The role of antibody concentration and avidity in antiviral protection.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Effect of pH on reactivity of monoclonal antibodies to Chlamydia

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Analytical approaches to the study of monoclonal antibody stability

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Passive immunization against hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

High titer multiple dose therapy with HBIG in newborn infants of HBsAg positive mothers

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Prevention of colonization of Streptococcus mutans by topical application of monoclonal antibodies in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Prevention of varicella by zoster immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Systemic and topical immunoglobulin treatment in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Human antibodies by design

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Intranasal antibody prophylaxis for protection against viral disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Controlled vaginal delivery of antibodies in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

TB vaccines: global solutions for global problems

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900355-5

7 January 2021

10.1016/S1286-4579(00)00355-5

Identifiers

DOI

1 reference

30 July 2017

1 reference